International Soy Experts Meeting in Argentina Called by the Round Table on Responsible Soy Association (RTRS)
BUENOS AIRES, Argentina, March 30 /PRNewswire/ -- The Development Group of
the international organization Round Table
on Responsible Soy Association
(RTRS) met in the city of Buenos Aires in order to design the final document
on "Responsible Soy Principles and Criteria."
JCI table of contents: April 22, 2008
EDITOR'S PICK: Two types of image are better than one for analyzing tumors
Doctors treating individuals with cancer would find a noninvasive method to determine the amount of oxygen in a tumor very useful, because low levels of oxygen in a tumor have been linked to a poor outcome. A new meth...
JCI online early table of contents: March 6, 2008
EDITOR'S PICK: Pinpoint accuracy: DNA vaccines that home in on DCs are more potent
One strategy being pursued to develop new vaccines against infectious diseases is DNA vaccination. The idea is that following administration of a DNA vaccine, the body converts the information in the DNA vaccin...
JCI table of contents: Dec. 3, 2007
EDITOR'S PICK: Promising approach to a more effective sunscreen
Chronic exposure to the sun increases the risk of an individual developing skin cancer because UV light from the sun can cause genetic mutations that enable cells in the skin to grow in an uncontrolled manner. Hope for a new sun...
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
...tion Reform Act of 1995.
Amicus Therapeutics,...6 22,439,893 22,615,951
Amicus Therapeutics,...6 22,618,026
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... for the three months to
June 30, 2009 (2008: $64.8 million). The following table
provides an analysis
of Shire's royalty income:
Product ...ts previously
classified as held for sale.
Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
...Royalty and Other Revenue $3,780 $-
Total Revenues $708,408 $596,432
The following table
presents condensed consolidated cash flow data for the six months ended June 30, 2009 and June 30, 2008:
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
...eet, the Statement of change in
Equity, the Cash Flow Statement and the Cap table
are presented below.
Income Statement (1 January - 30 June 2009)
... Balance sheet, Statement of Change in Equity, Cash
Flow statement, and Cap table
through this link:
New Report Just Published: World Prostate Cancer Therapeutics Market Report
... Prostate Cancer
Therapeutics Market II-2
1: Sales of FDA Approved Prostate Cancer Hormonal
Therapeutics Foster Growth II-6
2: New Incidences of Prostate Cancer (in '000)
corresponding Graph/Chart) II-6
3: New Cancer Cases Diagnosed in the US in 2007:
New Report Just Published: World Endoscopy Systems Market Report
2. Competitive Scenario II-7
1: Leading Players in the Global Endoscopy Market
Rigid Endoscope II-8
2: Leading Players in the Global Rigid Endoscope
Flexible Endoscopes II-8
3: Leading Players in the Global Flexible Endoscop...
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
... alfa achieved similar efficacy regardless of fertilization procedure; number of embryos transferred; or day of embryo transfer;(1) as detailed in the table
Overall IVF ICSI Single Double Day 3 Day 5
N=1506 N=481 N=830 N=...
Spherix Announces Termination of Arla License Agreement
...naturally in small amounts in dairy products. It is a highly soluble white crystal or powder, can be produced with a physical bulk similar to ordinary table
sugar, and is 92% as sweet. In the U.S., based on over 10 years of animal, human, and other relevant use and safety data, Naturlose was determined to ...
Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
...aturally in small amounts in dairy products. It is a highly soluble white crystal or powder, can be produced with a physical bulk similar to ordinary table
sugar, and is 92% as sweet. In the U.S., based on over 10 years of animal, human, and other relevant use and safety data, Naturlose qualified as Gene...
Quest Diagnostics Announces Final Tender Offer Results
...to Purchase, dated May 19, 2009 and related Letter of Transmittal.
below identifies the principal amount of each series of Notes validly tende...as determined in accordance with the Acceptance Priority Level shown in the table
below, subject to the Tender Cap.
Cappella Inc. Secures $17.3 Million Series C Investment
...r a company which we believe has the potential to lead the field of bifurcation devices. The commercial expertise which the new investors bring to the table
in Europe, US and Japan is reassuring and will help to accelerate the company's marketing efforts of its device portfolio. Importantly, the continued ...
Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
...over the years, and refrain from rewarding only those who they bring to the table
at the 11th hour to profit from the years of work and patience on behalf of... We remain hopeful that the newly elected Board will convert value from the table
that has been set for them. To ensure the Company continues to function in...
New and Expanded Free Tutorials on UCSC Genome Browser Now Available
...ed tool for mining genomic data. The three tutorial suites now available include a general introduction to the genome browser, an introduction to the table
Browser and custom tracks functions of the Genome Browser, and an introduction to additional tools available, including Gene Sorter and VisiGene.
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
...umab did not add to the severe toxicities of either regimen, with no Grade 3-4 skin toxicities observed. The results of the study are presented in the table
Summary of Efficacy Parameters - Reddy BK et al study:
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
...sion or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: table
To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red bl...
Frost & Sullivan: Lower Import Duties and Rising Customer Demand to Boost Russian Electronics Manufacturing Market
...s such as automotive and consumer electronics.
If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table
of contents, then send an e-mail to Joanna Lewandowska, Corporate Communications, at firstname.lastname@example.org " target="_new"> joanna.lewandowsk...
Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development
...n the U.S. and China, is pleased to announce the recent addition of Dr. Chris Huber as Director of Chemical Development.
Dr. Huber brings to the table
over 15 years experience in the pharmaceutical industry (early and late stage), developing process technology for API manufacturing of small molecules...
Rodobo International, Inc. Reports Q2 and First Half of 2009
...r the fiscal year ended
September 30, 2008 and to other reports filed from time to time by Rodobo with
the Securities and Exchange Commission.
RODOBO INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE
FOR THE SIX AND THREE MONTHS ENDED...
Solutia Reports First Quarter 2009 Results
...s sole lead arranger and sole bookrunner for the German term loan.
below is provided to assist the reader with comparability between the first...---------- -----
(1) See table
of Summary of Events Affecting Comparability
United Therapeutics Reports First Quarter 2009 Financial Results
Research and Development Expenses
below summarizes research and development expenses...ng, General and Administrative Expenses
below summarizes selling, general and administrati...ings Before Non-Cash Charges
The following table
provides a reconciliation of net income to earning...
BioMarin Announces First Quarter 2009 Financial Results
...rial items and the tax effect of the
adjustments. Please see the table
provided at the end of this
press release for a full reconciliati...ation of these measures to the estimated GAAP net income is detailed in the table
provided at the end of the press release.
BioMarin believes that this ...
Shire begins the year with a strong performance
... 3. Royalties
Royalty revenue decreased by 22% to $50.6 million for the three months to
March 31, 2009 (2008: $65.1 million). The following table
analysis of Shire's royalty income:
Royalties Year on year
Caliper Life Sciences Reports First Quarter 2009 Results
... $26,394 (3%) 7%
(1) For purposes of comparing growth rates for each of the three principal areas of our business, the above non-GAAP table
reconciliations exclude revenues related to the PDQ and AutoTrace product lines divested in November 2008. The $343 of first quarter 2009 revenue inc...
Medarex Announces 2009 First Quarter Financial Results
...he year ended December 31, 2008.
The accompanying press release dated April 30, 2009 contains non-GAAP financial measures. The following table
reconciles the non-GAAP financial measures contained in the press release to the most directly comparable financial measures prepared in accordance wi...
ViroPharma Incorporated Reports First Quarter 2009 Financial Results
...etween GAAP and adjusted net income is provided in the Consolidated Statement of Operations - Reconciliation of GAAP Net Income to Adjusted Net Income table
included with this release.
The Company believes it is important to share these non-GAAP financial measures with shareholders as they better rep...
Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010
...m first-quarter 2008 to 34.0 percent. (Please see table
5 for the calculation of adjusted prescription vol....96 in the first quarter of 2008. (Please refer to table
6 for a reconciliation of EBITDA to reported net i... (In millions, except for per share data)
Eklin Medical Systems to Showcase RapidStudy(TM) CDx Digital Radiography Systems at CVC East
...ystems provide excellent radiographs in seconds and can be retrofitted into most existing x-ray tables, or included with the newest Eklin custom x-ray table
specifically designed for digital imaging. In addition, other digital modules can be added as practice growth dictates.
"Every practice has its o...
SiliconSky GPS Designs First AGPS-Enabled Asthma Inhaler for Landmark Research Program
...rch database in real-time, where information could be compiled, managed and interpreted.
SiliconSky GPS brought its engineering heritage to the table
when designing the GPS-enabled inhaler. Its team has been a part of the design and engineering groups of some the world's most interesting GPS product...
China Biologic Products Announces Strong 2008 Results
...share in 2007.(*)
(*) Excludes Stock Based Compensation ("SBC"). See table
1 for a
reconciliation of Net Income and EPS to exclude SBC.
...ormance. A reconciliation of the adjustments to GAAP
results appears in the table
accompanying this press release. This additional
non-GAAP information is no...
International Isotopes Inc. Announces Year End Financial Results
...85 or 19.4%. The overall increase in revenue was the result of a significant increase in the performance of several business segments. The following table
provides a brief summary of the revenue performance in each of the Company's business segments.
Business Segment Area 2008 ...
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
...eration classified as discontinued operations (see table
Reconciliation by Geography below)....s business due to
changes in project mix. (See the table
titled Reconciliation of GAAP to
Non-GAAP below). ...ied as
discontinued operations. See table
below titled Discontinued
Publication of Shire plc's Annual Report 2008
the year to December 31, 2008 was $156.0 million compared to a net loss of
$1,451.8 million in 2007.
The following table
provides an analysis of the Group's total revenues by
Year to December 31, 2008 2007 Chan...
Informex Survey Shows Innovation Remains a Priority for 2009 and Beyond
...top five products and services requested at InformexUSA 2009 can be seen in table
1: Top Five Requests from InformexUSA 2009 Attendees
Elk Run Developers Announce Partnership with Leading Life Sciences Firm
...e transformative for the region," said Tower founder and CEO, Stephen Marks, Sr.
Burrill, led by founder and CEO G. Steven Burrill, brings to the table
an exclusive focus and expertise in the life sciences, with activities in private equity, venture capital, merchant banking and media and nearly $1B u...
Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results
... (5%) 7%
For purposes of comparing growth rates for each of the three principal areas of our business, the above non-GAAP table
reconciliations exclude the following:
(1) Reflects elimination of certain collaboration-related microfluidic
license and contract revenu...
Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
...lion compared to the previously reported charge of $2.667 billion.
below reconciles the Company's updated fourth quarter financial results to those previously reported. The adjustments in the table
are also reflected in the Company's Form 10-K, which will be filed tomorrow...